MD Anderson Cancer Centre

Houston, Texas 77030-4009

3 studies enrolling now · 11 studies all time

What they study most

Advanced Melanoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Castration-Resistant, Cervical Cancer, Differentiated Thyroid Cancer, Graft Vs Host Disease, Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer, Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Indolent Systemic Mastocytosis, Leukemia, B-cell

Studies at this site

• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — Recruiting now
• TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention — Recruiting now
• FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery — Recruiting now
• Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia — Recruiting now
• Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma — Completed
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Running, not enrolling
• 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) — Stopped early
• Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) — Running, not enrolling
• Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer — Completed
• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis — Completed
• A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. — Completed